B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 31.6 SEK 1.94%
Market Cap: kr2.1B

Net Margin

-132.3%
Current
Improving
by 338.9%
vs 3-y average of -471.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-132.3%
=
Net Income
kr-323.9m
/
Revenue
kr244.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-132.3%
=
Net Income
kr-323.9m
/
Revenue
kr244.8m

Peer Comparison

Country Company Market Cap Net
Margin
SE
BioInvent International AB
STO:BINV
2.1B SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD
Loading...

Market Distribution

Lower than 85% of companies in Sweden
Percentile
15th
Based on 2 084 companies
15th percentile
-132.3%
Low
-5 565 412.8% — -5.3%
Typical Range
-5.3% — 7.5%
High
7.5% — 12 228%
Distribution Statistics
Sweden
Min -5 565 412.8%
30th Percentile -5.3%
Median 3%
70th Percentile 7.5%
Max 12 228%

BioInvent International AB
Glance View

Market Cap
2.1B SEK
Industry
Biotechnology

BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

BINV Intrinsic Value
49.65 SEK
Undervaluation 36%
Intrinsic Value
Price
B
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-132.3%
=
Net Income
kr-323.9m
/
Revenue
kr244.8m
What is BioInvent International AB's current Net Margin?

The current Net Margin for BioInvent International AB is -132.3%, which is above its 3-year median of -471.2%.

How has Net Margin changed over time?

Over the last 3 years, BioInvent International AB’s Net Margin has decreased from -13.8% to -132.3%. During this period, it reached a low of -1 058.9% on Sep 30, 2024 and a high of -13% on Dec 31, 2022.

Back to Top